Aurora Fine Chemicals LLC

Your GLP Contract Research Organisation of Choice

EPP specialises in analytical, environmental sciences and research & development to help companies achieve product registration around the world with over 27 years experience.

EPP can provide support for REACH testing - we offer ecotoxicology, environmental fate and physico-chemical testing. We have the capacity and know-how to handle your studies with ease and efficiency.

We work within the agrochemical, human & animal pharmaceutical and industrial chemical sectors.

Why choose EPP:

We are your GLP contract research organisation of choice combining value for money with superior quality of services, delivered by our experienced and technically expert scientists. We enlighten and empower our clients leading to smoother product registration.

We deliver this aim by providing integrated and specialist analytical and development services, of consistently superior quality, founded upon our expert competencies in screening and synthesis, analytical services including phys-chem and environmental sciences.

Our innovative approach and unequaled performance confirms our position as a trusted, reliable partner and the CRO of choice.

We are time and cost conscious and our practical tailored approach ensures we are well priced. Outcomes are important to everyone and developing long term partnerships with customers enables us to repeatedly deliver and bring cost effectiveness.

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,700 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence.

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. The small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is advancing to a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II for treatment of non-infectious uveitis. Please visit www.activebiotech.com for more information.

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Our proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring.

Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$6.5 billion molecular diagnostics market. Biocartis employs over 500 people and is headquartered in Mechelen, Belgium. Further information? Visit www.biocartis.com

With 97 years of successful pharmaceutical experience, PLIVA is today a member of the Teva Group, one of the largest global pharmaceutical companies. We at PLIVA are dedicated to providing our customers with high quality, affordable medicines for a better quality of life.

PLIVA is the largest pharmaceutical company in Croatia and one of the leading companies in Southeast Europe thanks to its highly competent employees, innovative technologies and continuous investments in production. PLIVA is also one of the major exporters in Croatia with over 80% of products intended for exports, and its major markets are Croatia, the USA and Russia.

PLIVA's production portfolio includes a high number of finished dosage forms covering almost all therapeutic groups and active pharmaceutical ingredients. Focused on development of generic and niche products, PLIVA has the broadest portfolio of generic medicines in Central and Eastern Europe.

Thanks to the approvals by the US Food and Drug Administration (FDA), the British Medicines and Healthcare Products Regulatory Agency (MHRA) and those of other relevant European agencies, PLIVA is one of the manufacturers complying with the highest global quality standards required for international markets.

PLIVA's success and status may be largely attributed to its in-house research and development of finished dosage forms and active pharmaceutical ingredients, and Zagreb is therefore today one of the leading R&D centres in the Teva Group.

In addition to Croatia, PLIVA successfully operates in Southeast European markets, ie. in Bosnia and Herzegovina, Slovenia, Serbia, Montenegro and Macedonia.